Autosomal Dominant Intermediate Charcot-Marie-Tooth Disease (CMT-DI)

Autosomal dominant intermediate Charcot-Marie-Tooth disease (CMT-DI) is an inherited nerve disorder that slowly damages the long peripheral nerves supplying the feet, legs, hands, and arms. “Intermediate” means the electrical speed of the nerves (motor nerve conduction velocity) is in the middle range—neither as slow as classic demyelinating CMT (CMT1) nor as normal as axonal CMT (CMT2). In many families the nerve speeds fall roughly between ~25–45 meters/second, and different relatives can show mixed features of myelin and axon damage. Because it is autosomal dominant, one altered gene copy is enough to cause the illness and each child of an affected parent has a 50% chance to inherit it. MedlinePlus+3NCBI+3PMC+3

Autosomal Dominant Intermediate Charcot-Marie-Tooth disease is an inherited nerve disease. It damages long nerves to the feet and hands. People slowly develop weakness in the lower legs and hands. They often have high arches, hammer toes, ankle sprains, and later hand weakness. “Intermediate” means nerve tests show features between “demyelinating” and “axonal” types. It is usually passed from a parent (autosomal dominant). Many different genes can cause it. A well-known cause is INF2 gene changes; this subtype can rarely be linked to a kidney problem called focal segmental glomerulosclerosis (FSGS). There is no proven cure yet. Care focuses on rehab, bracing, pain control, and foot care. Genetic counseling is important. Charcot-Marie-Tooth Association+4NCBI+4PubMed+4

Other names

Doctors and genetics sites also call this condition Dominant Intermediate CMT (CMT-DI) or Hereditary motor and sensory neuropathy, dominant intermediate. Specific lettered subtypes are used when the gene is known: CMTDIA, CMTDIB, CMTDIC, CMTDID, CMTDIE, CMTDIF, CMTDIG. These labels reflect either the mapped chromosome region (A) or the causal gene (B–G). PMC+2PMC+2

Types

Seven autosomal-dominant intermediate subtypes are recognized:

• CMTDIA – linked to chromosome 10q24.1–q25.1 (gene not yet identified in the original mapping families). PMC+1

• CMTDIB – caused by DNM2 variants (dynamin-2; endocytic/vesicle trafficking protein). NCBI+1

• CMTDIC – caused by YARS1 variants (tyrosyl-tRNA synthetase). PMC+1

• CMTDID – caused by MPZ variants (myelin protein zero). PMC+1

• CMTDIE – caused by INF2 variants and may occur with kidney disease called focal segmental glomerulosclerosis (FSGS). New England Journal of Medicine+1

• CMTDIF – caused by GNB4 variants (G-protein β4 subunit). PMC+1

• CMTDIG – caused by NEFL variants (neurofilament light chain). NCBI+1

These subtypes all share an “intermediate” nerve-conduction pattern and a typical CMT clinical picture (high arches, distal weakness, absent ankle reflexes), but each gene nudges the biology in a different way. NCBI

---

Causes

In CMT-DI, “cause” means a genetic change that alters nerve biology. Below are the main gene-level causes and the key biological pathways they disturb.

1. DNM2 (CMTDIB) – Dynamin-2 mutations disrupt membrane fission/endocytosis in Schwann cells and axons, producing mixed myelin and axonal injury and intermediate nerve speeds. dnatesting.uchicago.edu

2. YARS1 (CMTDIC) – Tyrosyl-tRNA synthetase defects impair protein translation and non-canonical signaling, weakening long axons and causing intermediate neuropathy. PMC+1

3. MPZ (CMTDID) – Myelin protein zero mutations hinder myelin compaction and axon-Schwann cell adhesion, creating both demyelinating and axonal stress. PMC+1

4. INF2 (CMTDIE) – Inverted formin-2 mutations disturb actin dynamics in Schwann cells and podocytes, linking neuropathy with FSGS in some families. New England Journal of Medicine+1

5. GNB4 (CMTDIF) – G-protein β4 variations alter GPCR signaling that neurons and Schwann cells use, leading to intermediate conduction changes. PMC+1

6. NEFL (CMTDIG) – Neurofilament light mutations compromise the axonal cytoskeleton; some families show intermediate velocities rather than pure axonal patterns. NCBI

7. CMTDIA locus (10q24–q25) – A mapped region with dominant intermediate phenotype; the original causal gene remained elusive in the first families. PMC+1

8. Phenotypic overlap within families – Even with the same mutation, some relatives show demyelinating-range speeds while others show axonal-range speeds, creating an overall “intermediate” family profile. NCBI

9. Combined myelin and axon stress – Intermediate CMT reflects simultaneous injury to myelin and axons rather than a single compartment, explaining the mid-range velocities. Muscular Dystrophy Association+1

10. Dominant-negative effects – Some mutations produce abnormal proteins that interfere with the normal copy (e.g., structural myelin or cytoskeletal proteins), amplifying damage. (Conceptual mechanism across CMT genes.) PMC

11. Haploinsufficiency – A single functional copy may not make enough protein for normal nerve function in long axons, predisposing to length-dependent weakness. (General inherited neuropathy mechanism.) PMC

12. Protein misfolding and ER stress – Misfolded myelin or neuronal proteins can stress Schwann cells and axons, contributing to mixed pathology. (Mechanistic reviews of CMT.) PMC

13. Cytoskeletal trafficking defects – Disrupted microtubule/actin dynamics (e.g., INF2) impair organelle movement and myelin maintenance. Nature

14. Vesicle trafficking/endosomal defects – Dynamin-2–related endocytosis problems alter membrane turnover at nodes of Ranvier and paranodes. dnatesting.uchicago.edu

15. Abnormal neuron–Schwann cell signaling – Faulty signaling across the axon–glia unit (e.g., MPZ-mediated adhesion) destabilizes conduction. PMC

16. Axonal cytoskeleton instability – NEFL variants weaken neurofilaments, predisposing to distal axonal dying-back with intermediate speeds. NCBI

17. GPCR signal imbalance – GNB4 changes perturb second-messenger pathways controlling Schwann-cell differentiation and neuronal excitability. PMC

18. Actin-dependent node/paranode defects – INF2-driven actin remodeling errors can reshape nodal architecture needed for fast saltatory conduction. ScienceDirect

19. De novo mutations – Some patients have new (not inherited) pathogenic variants in these genes and present with classic CMT-DI. ScienceDirect

20. Classification nuance – Strict velocity cutoffs can misclassify some children with CMT1A as “intermediate,” underscoring why gene testing is essential for cause-finding in suspected CMT-DI. PubMed

---

Common symptoms

1. Slowly progressive foot weakness – The ankle and foot muscles weaken first; walking on heels or toes becomes hard. People may trip or feel “tired ankles.” NCBI

2. Foot drop – The front of the foot does not lift well during walking, causing a high-stepping or slapping gait. NCBI

3. High-arched feet (pes cavus) – Over years, foot shape changes and arches become high; some develop hammertoes. NCBI

4. Loss of ankle reflexes – Tapping the Achilles tendon produces little to no reflex. NCBI

5. Numbness or reduced feeling – Vibration and pinprick sensation fade in the toes and feet, later the fingers. NCBI

6. Burning or tingling – Some people feel pins-and-needles or mild neuropathic pain in a length-dependent pattern. NCBI

7. Calf muscle thinning – Calves look slimmer due to distal muscle atrophy; the legs can have a “stork-leg” appearance in advanced cases. NCBI

8. Hand weakness – Fine motor tasks (buttons, keys, jar lids) become difficult as hand muscles weaken after the legs. NCBI

9. Balance trouble – Unsteady walking, especially in the dark or on uneven ground, because both strength and sensation are affected. NCBI

10. Cramps and fatigue – Overworked proximal muscles compensate for weak distal muscles, causing cramps or fatigue with exertion. NCBI

11. Areflexia in knees over time – Reflex loss can climb from ankles to knees as the neuropathy progresses. NCBI

12. Hand tremor (in some families) – A coarse tremor can accompany inherited neuropathies in select genotypes. NCBI

13. Cold intolerance in feet – Poor axonal function can make feet feel unusually cold or uncomfortable. NCBI

14. Walking endurance declines – Long distances become hard; some people need ankle-foot orthoses (AFOs) for stability. NCBI

15. Kidney signs in CMTDIE – A special warning sign for the INF2 subtype is urinary protein (proteinuria) or swelling from FSGS; kidney checks are advised. Charcot-Marie-Tooth Association+1

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. Neuromuscular exam – The clinician checks distal strength (ankle dorsiflexion, toe extension, intrinsic hand muscles), tone, and reflexes; CMT-DI typically shows distal weakness and reduced ankle reflexes. NCBI

2. Sensory exam – Vibration (tuning fork), light touch, pinprick, and position sense are tested; length-dependent loss supports a peripheral neuropathy. NCBI

3. Gait analysis – Observation for foot drop, high-stepping, and poor heel-toe walking; useful to document progression and need for braces. NCBI

4. Skeletal/foot inspection – Look for pes cavus, hammertoes, calluses; orthopedic deformities are common in CMT. NCBI

5. Family history & inheritance pattern – A careful pedigree often shows autosomal-dominant transmission; still, de novo cases occur. MedlinePlus

B) Manual/functional tests (simple office or bedside maneuvers)

6. Heel-walk and toe-walk – Early weakness of ankle dorsiflexors or plantarflexors becomes obvious with these tasks. NCBI

7. Single-leg stance & tandem gait – Quick balance screens that reveal sensory ataxia and distal weakness in CMT. NCBI

8. 9-Hole Peg Test or grip dynamometry – Tracks fine motor decline in the hands over time. NCBI

9. Functional walking tests (e.g., 10-meter walk) – Simple, repeatable measures to monitor disease impact and brace benefit. NCBI

10. Romberg test – Worsening sway with eyes closed indicates impaired proprioception from large-fiber neuropathy. NCBI

C) Laboratory & pathological studies

11. Targeted or panel-based genetic testing – The most definitive test. Modern CMT panels look for DNM2, YARS1, MPZ, INF2, GNB4, NEFL and many other neuropathy genes, and they confirm the CMT-DI subtype when positive. NCBI+2preventiongenetics.com+2

12. Copy-number testing for PMP22 – Even when “intermediate” is suspected, clinicians often first exclude PMP22 duplication/deletion (CMT1A/HNPP) because nerve speeds can overlap in children. PubMed

13. Basic neuropathy labs – Glucose/A1c, B12, TSH, SPEP, and others help rule out acquired causes that can mimic CMT but are not inherited. (Useful for differential diagnosis.) NCBI

14. Urinalysis and kidney panel in suspected CMTDIE – Screening for proteinuria and kidney function is recommended if an INF2 mutation is found or suspected. Charcot-Marie-Tooth Association

15. (Occasionally) Nerve biopsy – Rarely needed now; when performed, intermediate CMT may show both demyelinating and axonal changes (a mixed pattern). Muscular Dystrophy Association

D) Electrodiagnostic tests

16. Motor nerve conduction studies (NCS) – This is the hallmark test. In CMT-DI, median motor conduction velocities are typically intermediate (often about 25–45 m/s), not as slow as CMT1 and not normal as in some CMT2. Amplitudes may be reduced from axonal loss. NCBI+1

17. Sensory NCS – Sensory responses in the sural and median nerves are often reduced or absent, consistent with a length-dependent sensorimotor neuropathy. NCBI

18. EMG (needle electromyography) – Shows chronic denervation/reinnervation in distal muscles; helps stage severity and exclude mimics (e.g., motor neuron disease). NCBI

19. Late responses (F-waves/H-reflex) – Prolonged or absent late responses reflect demyelinating elements in a mixed neuropathy. NCBI

E) Imaging and structural tests

20. Musculoskeletal imaging or nerve ultrasound/MRI (selected cases) – Foot X-rays document deformities; peripheral nerve ultrasound or MRI can show nerve enlargement in some genotypes (e.g., hypertrophy reported with INF2 variants). These tools are adjuncts, not substitutes for genetics and NCS. PubMed

Non-pharmacological (no-medicine) treatments

(each item includes description, purpose, mechanism)

1. Regular aerobic exercise — Brisk walking, cycling, or swimming 20–40 minutes most days. Purpose: keep heart-lung fitness and endurance. Mechanism: improves muscle oxidative capacity and overall function; may reduce fatigue in neuropathy. Evidence supports exercise for function in CMT, though studies are small. PubMed+1

2. Progressive resistance training — Light weights or bands 2–3 days/week under therapist guidance. Purpose: slow loss of strength. Mechanism: muscle fiber hypertrophy and neural recruitment; small trials suggest benefit and safety. PubMed

3. Balance training — Single-leg stands near support, wobble board, tandem walking. Purpose: cut falls and ankle sprains. Mechanism: improves proprioception and postural reflexes, which are impaired in neuropathy. NCBI

4. Stretching program — Daily calf, hamstring, plantar fascia, and hand stretches. Purpose: prevent contractures and maintain range. Mechanism: lengthens tight muscle-tendon units that shorten with weakness and imbalance. Lippincott Journals

5. Custom ankle-foot orthoses (AFOs) — Light carbon-fiber or plastic braces. Purpose: treat foot drop, improve push-off, and reduce trips. Mechanism: substitutes for weak dorsiflexors; improves gait mechanics. Evidence base is limited but widely used in practice. The Foundation for Peripheral Neuropathy+1

6. In-shoe supports and footwear — High-top shoes, lateral wedges, cushioned insoles, wide toe box. Purpose: stabilize ankle and reduce pressure points. Mechanism: redistributes load and limits inversion sprains common in cavovarus feet. PMC

7. Hand therapy / occupational therapy — Grip strengthening, pinch practice, adaptive tools (built-up pens, jar openers). Purpose: preserve independence in daily tasks. Mechanism: task-specific practice and assistive devices compensate for distal weakness. NCBI

8. Energy-conservation skills — Pacing, rest breaks, plan errands. Purpose: manage fatigue. Mechanism: spreads muscle workload and prevents overuse. NCBI

9. Skin and foot care education — Daily checks, nail care, callus management. Purpose: prevent sores and infections. Mechanism: reduced sensation increases injury risk; early care prevents complications. NCBI

10. Fall-prevention home changes — Night lights, remove loose rugs, bathroom grab bars. Purpose: cut falls. Mechanism: environmental modification reduces hazard exposure. NCBI

11. Orthopedic evaluation early — For progressive cavovarus foot. Purpose: decide if bracing is enough or surgery is needed. Mechanism: timely correction preserves function and shoe wear. PMC

12. Ankle proprioceptive sleeves or taping — External support during activity. Purpose: reduce sprains. Mechanism: enhances joint position cues to the brain. Lippincott Journals

13. Hydrotherapy — Exercise in warm pool. Purpose: low-impact conditioning. Mechanism: buoyancy reduces joint load while allowing movement practice. Lippincott Journals

14. Pain self-management strategies — Heat/cold, relaxation, sleep hygiene. Purpose: reduce chronic pain burden. Mechanism: modulates pain pathways and improves coping. NCBI

15. Nerve-protective lifestyle — No smoking, moderate alcohol, control diabetes/thyroid/B12. Purpose: remove extra nerve stressors. Mechanism: smoking and metabolic issues can worsen neuropathy. NCBI

16. Workplace accommodations — Ergonomic keyboards, foot rests, schedule flexibility. Purpose: sustain employment. Mechanism: reduces repetitive strain and fatigue. NCBI

17. Education about neurotoxic drugs — Learn which medicines can worsen CMT (e.g., vincristine, some taxanes). Purpose: avoid preventable nerve injury. Mechanism: these drugs can damage peripheral nerves; alternatives may be safer. Charcot-Marie-Tooth Association+1

18. Genetic counseling — For family planning and testing decisions. Purpose: understand inheritance, testing, and risks to children. Mechanism: autosomal-dominant transmission means 50% risk to each child. NCBI

19. Support groups / patient organizations — CMTA, foundations. Purpose: practical tips, braces info, trials. Mechanism: community resources speed access to care pathways. Charcot-Marie-Tooth Association

20. Structured, therapist-led programs — PT/OT plans with goals and regular review. Purpose: coordinate exercise, bracing, and safety. Mechanism: multidisciplinary care improves outcomes in CMT. NCBI

---

Drug treatments

Important note: Right now, no drug is FDA-approved to stop or reverse CMT. Medicines below are used to treat symptoms like neuropathic pain, cramps, or musculoskeletal pain. Doses here are from FDA labels for the indication named on that label (often neuropathic pain such as diabetic peripheral neuropathy or post-herpetic neuralgia). Always tailor to the individual and the prescriber’s judgment.

1. Duloxetine (Cymbalta) — Class: SNRI. Typical dose/time: For diabetic peripheral neuropathic pain, label-recommended 60 mg once daily; higher doses add side effects without extra benefit. Purpose: reduce neuropathic pain. Mechanism: boosts serotonin/norepinephrine to dampen pain pathways. Common side effects: nausea, somnolence, dry mouth, constipation, sweating. FDA Access Data+1

2. Pregabalin (Lyrica / Lyrica CR) — Class: α2δ ligand anticonvulsant. Dose/time: For DPN or PHN, 150–300 mg/day initially; may titrate to 300–600 mg/day depending on indication and renal function; adjust for kidney disease. Purpose: neuropathic pain. Mechanism: reduces calcium-channel-mediated neurotransmitter release. Side effects: dizziness, somnolence, edema, weight gain. FDA Access Data+1

3. Gabapentin (Neurontin) — Class: α2δ ligand. Dose/time: For post-herpetic neuralgia, titrate from 300 mg to 900–1800 mg/day in divided doses; evidence across 1800–3600 mg/day. Purpose: neuropathic pain. Mechanism: similar to pregabalin. Side effects: dizziness, somnolence, ataxia. FDA Access Data

4. Capsaicin 8% patch (Qutenza) — Class: TRPV1 agonist topical. Dose/time: Clinic-applied patch to painful area; labeled for PHN and diabetic neuropathic pain of the feet. Purpose: focal neuropathic pain. Mechanism: defunctionalizes nociceptor terminals. Side effects: local burning/erythema; avoid eye exposure. FDA Access Data+1

5. Lidocaine 5% patch (Lidoderm) — Class: local anesthetic topical. Dose/time: Up to 3 patches once daily (12 hours on/12 hours off) for PHN. Purpose: localized neuropathic pain. Mechanism: sodium-channel block in cutaneous nerves. Side effects: skin irritation; use on intact skin only. FDA Access Data+1

6. Ibuprofen (Motrin) — Class: NSAID. Dose/time: Prescription strengths 400–800 mg per dose as directed; use lowest effective dose for shortest time. Purpose: musculoskeletal pain from overuse or minor injuries. Mechanism: COX inhibition lowers prostaglandins. Side effects: GI upset/bleeding, kidney risk, CV risk with chronic use. FDA Access Data

7. Naproxen / Naproxen sodium — Class: NSAID. Dose/time: Controlled-release or OTC naproxen sodium per label; use minimal effective dose. Purpose: aches and inflammatory pain. Mechanism: COX inhibition. Side effects: boxed warnings for GI bleeding and CV risk; avoid in late pregnancy. FDA Access Data+2FDA Access Data+2

8. Tramadol / Tramadol ER (Ultram/Ultram ER) — Class: opioid analgesic with SNRI activity. Dose/time: Use lowest effective dose; ER product has boxed warnings for addiction and respiratory depression. Purpose: second-line for severe pain when others fail. Mechanism: mu-opioid agonist and monoamine reuptake blockade. Side effects: nausea, dizziness, constipation, dependence, serotonin syndrome, seizure risk. FDA Access Data+1

9. Baclofen (oral or intrathecal) — Class: GABA_B agonist antispasmodic. Dose/time: Individual titration for spasticity (note: spasticity is not typical in CMT but baclofen is sometimes used for painful cramps). Purpose: reduce severe cramps/spasms. Mechanism: reduces excitatory neurotransmission in spinal cord. Side effects: sedation, dizziness; avoid abrupt stop. FDA Access Data+1

10. Tizanidine (Zanaflex) — Class: α2-adrenergic agonist antispasmodic. Dose/time: Start 2 mg, repeat q6–8h PRN up to 3 doses/day for spasticity (again, used selectively if cramps are prominent). Purpose: severe cramp relief. Mechanism: reduces polysynaptic reflex activity. Side effects: hypotension, sedation, dry mouth; watch interactions. FDA Access Data+1

11. Topical NSAID gel (e.g., diclofenac) — Class: NSAID topical. Dose/time: as per product label. Purpose: focal joint/soft tissue pain without systemic NSAID exposure. Mechanism: local COX inhibition. Side effects: skin irritation; lower systemic risks than oral. (Use FDA label of selected product.) FDA Access Data

12. Acetaminophen — Class: analgesic/antipyretic. Dose/time: per OTC label; keep under max daily dose. Purpose: mild to moderate pain when NSAIDs not suitable. Mechanism: central analgesic action. Side effects: liver toxicity with overdose. (Use FDA Drug Facts label.) FDA Access Data

13. Low-dose TCAs (e.g., amitriptyline) — Class: tricyclic antidepressant. Dose/time: bedtime dosing titrated by clinician for neuropathic pain (off-label). Purpose: neuropathic pain. Mechanism: serotonin/norepinephrine modulation, sodium channels. Side effects: anticholinergic effects, QT risk. (FDA label exists but neuropathic pain use is off-label.) FDA Access Data

14. SNRIs other than duloxetine (e.g., venlafaxine ER) — Class: SNRI. Dose/time: per label (depression/anxiety); neuropathic pain use is off-label. Purpose: alternative when duloxetine not tolerated. Mechanism: similar to duloxetine. Side effects: BP elevation, nausea. (Use FDA label; pain indication may be off-label.) FDA Access Data

15. Topical compounded agents (lidocaine ± others) — Class: local analgesics. Dose/time: individualized; evidence limited. Purpose: focal burning pain zones. Mechanism: sodium-channel blockade. Side effects: local irritation. FDA Access Data

16. Capsaicin low-strength cream — Class: TRPV1 agonist topical. Dose/time: several times daily. Purpose: minor focal neuropathic pain. Mechanism: depletes substance P, desensitizes nociceptors. Side effects: burning. (OTC Drug Facts.) FDA Access Data

17. Short steroid course for entrapment-related inflammation — Class: glucocorticoid. Dose/time: short, targeted courses only when clear inflammatory entrapment is present, supervised by clinician. Purpose: reduce local inflammatory pain. Mechanism: anti-inflammatory genomic effects. Side effects: glucose rise, mood change. (Use FDA label of specific steroid.) FDA Access Data

18. Botulinum toxin for painful foot deformity spasm (select cases) — Class: neuromuscular blocker. Dose/time: injected in specialist clinic. Purpose: reduce focal overactivity in imbalanced muscles. Mechanism: blocks acetylcholine release. Side effects: local weakness. (FDA labels exist for other indications; this use is off-label.) FDA Access Data

19. Opioid-sparing combinations — Class: multimodal analgesia. Dose/time: careful, short-term use only if other options fail. Purpose: rescue for severe flares. Mechanism: synergistic pain control. Side effects: dependence, constipation. FDA Access Data

20. Topical lidocaine + physical therapy — Class: local anesthetic + rehab. Dose/time: lidocaine patch cycles with PT blocks. Purpose: let patients tolerate exercises by lowering pain. Mechanism: peripheral sodium-channel block to allow graded loading. Side effects: skin irritation. FDA Access Data

Why these choices? CMT pain is neuropathic plus mechanical. Labels for duloxetine, pregabalin, gabapentin, capsaicin 8%, and lidocaine 5% cover neuropathic pain in other conditions and are commonly applied to CMT pain by analogy. Disease-modifying drugs for CMT are still investigational. NCBI

---

Dietary molecular supplements

1. Alpha-lipoic acid — Antioxidant used in diabetic neuropathy studies. Dose often used in studies: 600 mg/day. Function/mechanism: scavenges free radicals; may improve microcirculation and oxidative stress in nerves. Evidence in CMT is limited. Cochrane

2. Acetyl-L-carnitine — Supports mitochondrial fatty-acid transport. Dose: 500–1000 mg twice daily. Function: may aid nerve energy metabolism; small trials in other neuropathies. Evidence in CMT is limited. Cochrane

3. Coenzyme Q10 — Mitochondrial electron transport cofactor. Dose: 100–300 mg/day. Function: support ATP production; antioxidant. Benefit in CMT unproven. Cochrane

4. Vitamin D (if low) — Dose: per lab-guided replacement. Function: bone/muscle health; deficiency worsens weakness/falls. NCBI

5. Omega-3 fatty acids — Dose: ~1–2 g/day EPA+DHA. Function: anti-inflammatory membrane effects; symptomatic pain data is mixed. Cochrane

6. Curcumin — Dose: product-specific; many combine with piperine. Function: NF-κB modulation; theoretical anti-inflammatory effect in neuropathic pain pathways. Human evidence is limited. Cochrane

7. Magnesium — Dose: 200–400 mg elemental/day if diet is low. Function: may help muscle cramps in some people; evidence mixed. Avoid excess. Cochrane

8. Creatine monohydrate — Dose: 3–5 g/day. Function: may support strength training response; trials in CMT did not show clear benefit but generally safe with guidance. Cochrane

9. B-complex (B1/B6/B12) if deficient — Dose: lab-guided only. Function: co-factors for nerve health; excess B6 can itself cause neuropathy, so avoid high unsupervised doses. Cochrane

10. Polyphenol-rich diet (not a pill) — Berries, olive oil, greens, nuts. Function: anti-inflammatory dietary pattern to support general nerve and cardiovascular health. Evidence is indirect. NCBI

Note: Vitamin C did not help in CMT1A trials; supplements are not cures for CMT. Cochrane

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or regenerative drugs for Charcot-Marie-Tooth disease at this time. The FDA labeling database does not list any regenerative or stem-cell therapy indicated for CMT. Research pipelines include gene therapy, neurotrophin-based approaches, and other molecular strategies, but these are investigational and should be accessed only in registered clinical trials. Please avoid clinics offering unapproved “stem-cell cures.” NCBI

If you are interested in trials, ask your neurologist to check reputable registries and CMTA resources for study listings and gene-specific programs. Charcot-Marie-Tooth Association

---

Surgeries

1. Soft-tissue balancing (plantar fascia release, tendon lengthening) — What: releases tight plantar fascia and lengthens overactive tendons. Why: reduces cavus and clawing in flexible feet; improves shoe wear and pain. enmc.org

2. Tendon transfers (e.g., tibialis posterior or EHL transfer; peroneus longus to brevis) — What: move a stronger tendon to replace the action of a weak muscle (e.g., dorsiflexion). Why: corrects foot drop and muscle imbalance contributing to cavovarus. PMC+2upload.orthobullets.com+2

3. First metatarsal dorsiflexion osteotomy — What: cut and reposition the first metatarsal bone. Why: corrects forefoot-driven cavus and helps realign the arch. PubMed

4. Calcaneal osteotomy (valgus realignment) — What: heel-bone cut and shift. Why: re-centers the heel to correct hindfoot varus and improve gait. ScienceDirect

5. Fusion procedures (e.g., triple arthrodesis) for rigid deformity — What: fuse painful, stiff joints in severe cases. Why: pain relief and stable, plantigrade foot when flexibility is lost; joint-preservation is preferred when possible due to long-term stiffness concerns. enmc.org+1

Surgical goals are a plantigrade, brace-friendly foot, not “normal” strength. Choice depends on deformity pattern and flexibility. PMC

---

Preventions

1. Avoid neurotoxic medications when alternatives exist (especially vincristine, some taxanes). Always warn new doctors you have CMT. Charcot-Marie-Tooth Association+1

2. Wear supportive shoes and consider AFOs early to prevent falls and sprains. The Foundation for Peripheral Neuropathy

3. Do regular exercise (aerobic + strength) to preserve function. PubMed

4. Keep up stretching to prevent contractures. Lippincott Journals

5. Daily foot checks to catch blisters or sores early. NCBI

6. No smoking; limit alcohol to protect nerves. NCBI

7. Manage other conditions (diabetes, thyroid, B12) that can worsen neuropathy. NCBI

8. Keep vaccinations up to date to avoid infections that can set back rehab. NCBI

9. Use home safety steps (lights, clear floors, grab bars). NCBI

10. Genetic counseling for family planning and cascade testing. NCBI

---

When to see a doctor

See a neurologist and physiatrist for a baseline plan. Go sooner if you have more falls, new foot wounds, sudden worse pain, new numbness or weakness in the hands, rapidly changing foot shape, or signs of kidney trouble (foamy urine, swelling) in families with INF2-related disease. Ask your doctor before starting new medicines, especially chemotherapy, because some can harm nerves in CMT. NCBI+2NCBI+2

---

What to eat and what to avoid

Eat a whole-food pattern: vegetables, fruits, legumes, whole grains, nuts, fish, and olive oil. This supports weight control, heart health, and muscles, which all matter in CMT. Keep adequate protein to support training. Stay hydrated to ease cramps. Avoid excess alcohol, tobacco, and extreme crash diets. Supplements can help only if you have a deficiency or a clinician recommends them; megadoses can be harmful (for example, too much vitamin B6 can injure nerves). NCBI+1

---

Frequently asked questions

1) Is ADI-CMT curable?
Not yet. Treatments aim to keep you strong, steady, and safe. Trials for gene-specific therapies are ongoing. NCBI

2) What does “intermediate” mean?
It means nerve tests show speeds between classic demyelinating and axonal CMT. Clinically, it looks like a mix. PubMed

3) Will I end up in a wheelchair?
Most people walk for life with the right braces, therapy, and foot care. Some need canes or walkers as they age. NCBI

4) Which gene is most linked to dominant intermediate CMT?
Several genes can do this. INF2 is a key cause of the CMTDIE subtype and may be linked to kidney disease in some families. Charcot-Marie-Tooth Association+1

5) Why are my arches so high?
Muscle imbalance pulls the foot into cavovarus (high arch, inward heel). Bracing and, sometimes, surgery rebalance forces. PMC

6) Do exercises help?
Yes. Supervised aerobic and strength work can maintain function; studies are small but supportive. PubMed

7) Are there pills that fix the nerves?
No approved disease-modifying drugs yet. Pain medicines can help symptoms but do not repair nerves. NCBI

8) Can vitamins cure CMT?
No. Correct deficiencies (like vitamin D or B12) and consider targeted supplements with your doctor. Trials like vitamin C in CMT1A did not show benefit. Cochrane

9) Which medicines should I avoid?
Avoid clearly neurotoxic drugs when possible (e.g., vincristine; some taxanes). Always ask your prescriber to check. Charcot-Marie-Tooth Association+1

10) What if my pain is burning and patchy?
Topical options like lidocaine 5% or capsaicin 8% patches can help localized neuropathic pain. FDA Access Data+1

11) Do I need genetic testing?
Testing helps confirm the subtype and guides family planning; it also connects you to gene-specific trials. NCBI

12) When is surgery right?
When bracing fails and deformity is rigid or painful, surgery can realign the foot for better function and shoe wear. PMC

13) Is kidney screening needed for everyone?
If your family has INF2-related CMT, your doctor may check urine protein and kidney function because of a link with FSGS. New England Journal of Medicine

14) Can I play sports?
Yes, with braces and safety planning. Swimming and cycling are great. Avoid high-risk ankle-twist sports unless well supported. PubMed

15) Where can I learn more and find trials?
GeneReviews and CMTA are trusted starting points; your specialist can search current trials and registries. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.